Notification no. 41/2025, dated 30-04-2025 … Continue reading “CBDT Notifies Updated ITR-3 Applicable for AY 2025–26”
Author: Taxmann
The Research and Editorial Team is responsible for developing reliable and accurate content for the readers. The team follows the six-sigma approach to achieve the benchmark of zero error in its publications and research platforms. The team ensures that the following publication guidelines are thoroughly followed while developing the content:
- The statutory material is obtained only from the authorized and reliable sources
- All the latest developments in the judicial and legislative fields are covered
- Prepare the analytical write-ups on current, controversial, and important issues to help the readers to understand the concept and its implications
- Every content published by Taxmann is complete, accurate and lucid
- All evidence-based statements are supported with proper reference to Section, Circular No., Notification No. or citations
- The golden rules of grammar, style and consistency are thoroughly followed
- Font and size that's easy to read and remain consistent across all imprint and digital publications are applied
Non-Banking Financial Companies (NBFCs) are … Continue reading “NBFCs in India – Types | Regulations | RBI Framework”
Deendayal Antyodaya Yojana is a … Continue reading “Deendayal Antyodaya Yojana – Features and Objectives”
Capital Gains Exemption refers to … Continue reading “Capital Gains Exemption on Residential House Under Section 54”
1. Background On 30 April … Continue reading “SEBI Revises Cybersecurity Norms and Regulated Entities Thresholds”
On 30 April 2025, the … Continue reading “SEBI Consultation on IPO Share Dematerialisation Proposal”
1. Background On 29 April … Continue reading “RBI Mandates 3-Year Trade Record to Open Diamond Dollar Account”
On 30 April 2025, the Securities and … Continue reading “SEBI Depositories Amendment – Cooling-Off Period for Non-Independent Directors”
Global Financial Insights is a … Continue reading “ISSB Proposes Climate Disclosure Relief—Global Reporting Updates”
Case Details: AstraZeneca Pharma India … Continue reading “No AMP Adjustment When APA Margin is Followed | ITAT”
CA | CS | CMA